Date

2022-10

Author

Bas, Fatma Ulkem
Dikli, Sertan Ali
Tunçbağ, Nurcan

Metadata

Show full item record

This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.

Item Usage Stats

230
views

49
downloads

Cite This

During the tumor evolution, cancer driver mutations accumulate on some specific genes (oncogenes, tumor suppressors) which promote cell proliferation. Driver mutations generally show themselves as a deleterious mutation in the tumor-suppressor genes, such as p53. Similarly, proto-oncogenes can be mutated and turn into oncogenes, which, as the name implies, means the cancer-inducing genes being expressed higher than their trending levels. These biomarkers altogether are called cancer driver genes in the extent of this study. These specific genes and the driver network that they affect need to be understood and studied to help cancer research. Network models provide an insight into the mathematical projection of biological processes. Hypothetically, this might lead to an unbiased prediction of the affected pathways, response to cancer drugs, cellular state upon different mutations throughout the lifetime of the cell, gene expression. Cancer is a family of diseases that can lead to a typical phenotype that is uncontrollable cell proliferation, which shows a considerable variation among tissues. The network structures and the driver genes may differ across tissues. Therefore, tissue-specific modeling is crucial in cancer. This study uses network analysis and perturbations to predict driver genes and their associated subnetworks. For this purpose, we consider topological aspects such as node removal costs, centrality measures, or their localization tendencies in the network (e.g., the most populated region of the network by the drivers). Here, we constructed a pipeline to reveal driver subnetworks. Starting on a given tissue-specific protein-protein interaction (TSPPI) network, we trim the network to an optimal point without losing the driver genes. We performed a blind method in which the driver genes are not given initially to the algorithm until the testing period. We aimed to prevent a bias towards the most studied driver genes. We may summarize the pipeline as a method that uses a graph-based approach to predict genes that drive tumor progression. In this study, we performed first the Leiden community detection algorithm, followed by Generalized Network Dismantling with Reinsertion, and finally Personalized PageRank (PPR). We obtained the TSPPI networks for different tissues such as breast, colon, kidney, lung, ovary, and skin from the TissueNet V2 database and the driver gene information related to the corresponding tissues from the Cancer Genome Interpreter (CGI) Biomarkers database for testing. Leiden algorithm is a community detection method for the networks depending on the topological connections within each communities’ members; in other words, by using this method, we created subgroups of nodes that reveals the modules The tissue-specific communities were pre-processed to continue with the Generalized Network Dismantling with Reinsertion (GNDR). In summary, these two steps provide a node elimination strategy depending on the topological costs of removed nodes and return a list of removed nodes from the reference interactome resulting in the size reduction of the largest connected component. We selected the top 10% of removed node lists of each community from each TSPPI as the source nodes for the Personalized PageRank (PPR) algorithm. Then, we conducted the PPR algorithm on the original TSPPI network. Finally, we removed around 70% of the nodes losing less than 20% of the driver genes. Throughout the processes, the driver gene information was hidden from the pipeline and only used for the testing period. Utilizing the algorithms mentioned above with optimized parameters, we were able to reduce the initial size to 25% of each initial network, and the known driver genes were searched among these sets of genes and confirmed that more than half of the driver genes were still present in the remaining network as shown in Table 1. This algorithm found 74, 80 and 89 percent of the known driver genes for ovary, colon and breast cancer tissues, while reducing the network sizes to 31, 19.7 and 22.5 percent respectively. However; for the kidney, skin and lung tissues the driver counts were 60, 60 and 55 while the corresponding network sizes are 20, 21 and 22. In this view point, we can say the algorithm has been more succesful for the former 3 tissues, while the latter 3 tissues has a similar but less success. More detailed numbers can be found in the Figue 1.b as a table. We conducted pathway enrichment analysis and the results show that our subgraph show an enrichment in breast cancer tissue specific pathways such as Estrogen-dependent gene expression, and breast cancer pathways with the adjusted p-values of 4.3x10 -16 and 1.07x10 -7 . As well as many other cancer related pathways such as Mitotic G1 phase and G1/S transition with an adjusted p-value of 1.38x10 -18 . To conclude, these procedures can be used to reduce the computational burden of the following studies and provide promising candidates for the unknown driver genes.

URI

https://hibit2022.ims.metu.edu.tr
https://hdl.handle.net/11511/101338

Collections

Graduate School of Informatics, Conference / Seminar